Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02593708
Title Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michelle Melisko
Indications

Advanced Solid Tumor

Therapies

Neratinib + Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.